| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |